Immune-modulating peptide approved for hepatitis B in several countries.
Typical dose range: 1.6 mg
Frequency: 2 × weekly
Route: Subcutaneous
Half-life: ~2 h
Evidence level: Clinical (international)
Commonly run in 8–12 week cycles. Particularly popular for users dealing with persistent low-grade infections or post-viral fatigue.